Table 4 Pathogen-Associated Risk Factors for Severe CAP and Prognosis: An RNA + DNA mNGS Analysis of BALF and Blood Samples.
Pathogens | SCAP (survivor) vs Mild CAP | SCAP (death) vs Mild CAP | SCAP (death) vs SCAP (survivor) |
|---|---|---|---|
RNA + DNA mNGS of BALF | |||
Corynebacterium striatum | 15% vs 7.69% (P = 0.4990) | 20.83% vs 7.69% (P = 0.3005) | 20.83% vs 15% (P = 0.5493) |
Candida albicans | 15% vs 15.38% (P = 0.9732) | 29.17% vs 15.38% (P = 0.3509) | 29.17% vs 15% (P = 0.1726) |
Pneumocystis Jiroveci | 16.67% vs 0% (0.5649) | 16.67% vs 0% (P = 0.2756) | 16.67% vs 2.5% (P = 0.0409) |
Human cytomegalovirus (HCMV) | 27.5% vs 15.38% (P = 0.3778) | 33.33% vs 15.38% (P = 0.2405) | 33.33% vs 27.5% (P = 0.6210) |
RNA + DNA mNGS of blood | |||
Human cytomegalovirus (HCMV) | 12.5% vs 7.69% (0.6346) | 29.17% vs 7.69% (0.1298) | 29.17% vs 12.5% (0.0982) |
Torque teno virus (TTVs) | 40% vs 30.77% (P = 0.5508) | 50% vs 30.77% (P = 0.2597) | 50% vs 40% (P = 0.4350) |
Epstein-Barr virus (EBV) | 55% vs 38.46% (P = 0.3001) | 58.33% vs 38.46% (P = 0.2483) | 58.33% vs 55% (P = 0.7947) |
